期刊文献+

米非司酮联合甲氨蝶呤保守治疗异位妊娠的疗效观察 被引量:7

Efficacy Observation of Mifepristone Combined with Methotrexate Conservative Treatment for Ectopic Pregnancy
原文传递
导出
摘要 目的:观察米非司酮联合甲氨蝶呤(MTX)保守治疗异位妊娠的效果。方法:选择我院异位妊娠患者243例,按随机数字表法将入组患者分为米非司酮+MTX组(122例)和米非司酮组(121例)。观察并记录住院时间、阴道流血时间、β-绒毛膜促性腺激素(β-HCG)下降至正常时间、包块缩小时间、腹痛例数、转手术例数、造影通畅例数,了解治疗的安全性和有效性。结果:米非司酮+MTX组阴道流血时间、β-HCG下降至正常的时间、包块缩小的时间、腹痛的例数均显著优于米非司酮组(P<0.05),2组在出现副反应及输卵管通畅程度的比较上差异无统计学意义(P>0.05)。结论:米非司酮+MTX治疗异位妊娠疗效较好,安全性高。 To observe the therapeutic efficacy of mifepristone combined with methotrexate in the treatment of ec- topic pregnancy. METHODS: 243 patients with ectopic pregnancy in our hospital were randomly divided into mifepristone group (121 cases) and mifepristone combined with methotrexate group(122 cases) according to random number table. The length of stay, vaginal bleeding time, the time of fl-HCG dropping to normal, the time of mass reduction, abdominal pain, transfer surgery and case number of smooth radiography were observed and recorded. RESULTS : The vaginal bleeding time, the time of fl-HCG dropping to normal, the time of mass reduction, case number of abdominal pain in mifepristone combined with methotrexate group were signifi- cantly better than mifepristone group (P〈0.05). There was no statistical significance in adverse drug reaction and the degree of tubal patency between 2 groups (P〉0.05). CONCLUSION: Mifepriston combined with methotrexte in the treatment of ectopic pregnancy has mood efficacy and low ADRs.
出处 《中国药房》 CAS CSCD 北大核心 2011年第48期4566-4567,共2页 China Pharmacy
关键词 异位妊娠 米非司酮 甲氨蝶呤 Ectopic pregnancy Mifepristone Methotrexate
  • 相关文献

参考文献5

二级参考文献13

共引文献98

同被引文献67

  • 1霍娟.中西医结合治疗异位妊娠140例临床观察[J].现代中西医结合杂志,2005,14(10):1266-1266. 被引量:9
  • 2黄晓军,张晓薇,陈国勤.表皮生长因子在子宫肌瘤组织中表达和米非司酮的干预作用[J].中国妇幼保健,2006,21(22):3129-3132. 被引量:10
  • 3赵淑婷,张霞.围绝经期子宫肌瘤保守治疗的远期结局分析[J].广东医学,2007,28(7):1152-1153. 被引量:1
  • 4崔婷婷.中西医结合治疗异位妊娠的研究.中外健康文摘,2011,8(37):309-310.
  • 5Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century[J]. Contraception, 2010,82(5) :442.
  • 6Philippe B, Nathalie CB, Bart F, et al. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety[J]. Fertility and Sterility , 2011,96(5) : 1 175.
  • 7Smith CL, O' Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators[J]. Endocr Rev, 2004,25 ( 1 ) : 45.
  • 8Feng C, Meldrum S, Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone[J]. Int J Gynaecol Obstet,2010,109(2):121.
  • 9Liu Meiling, Shi Xinquan, Jia Mengchun. Differentially expressed genes in early gestational chorionic villi after administration of mifepristone[J]. Gynecological Endocrinol, 2011,27(6):371.
  • 10Narvekar N, Critchley HO, Cheng L, et al. Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor[J]. Hum Reprod, 2006,21(9):2 312.

引证文献7

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部